The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL
Open accessAbstract
Key Points: Expansion of PD-1+ CD3−CD56hiCD16-ve NK cells and PD-L1+ monocytes/macrophages is more prominent in cHL than DLBCL. PD-1 blockade reverses the immune evasion mediated by the interaction of PD-1+ NK cells and PD-L1+ monocytes/macrophages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
The biology of human natural killer-cell subsets
Cooper, M. A., Fehniger, T. A., & Caligiuri, M. A. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02060-9 · Cited by 2,975
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247
Caligiuri, M. A. (2008) · Blood · doi:10.1182/blood-2007-09-077438 · Cited by 1,905
Stromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G., Dave, S. S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,808
Inhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset
Cooper, M. A., Fehniger, T. A., Turner, S. C., Chen, K. S., Ghaheri, B. A., Ghayur, T., Carson, W. E., & Caligiuri, M. A. (2001) · Blood · doi:10.1182/blood.v97.10.3146 · Cited by 1,449
CD107a as a functional marker for the identification of natural killer cell activity
Alter, G., Malenfant, J. M., & Altfeld, M. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.08.008 · Cited by 1,410
Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
Steidl, C., Lee, T., Shah, S. P., Farinha, P., Han, G., Nayar, T., Delaney, A., Jones, S. J., Iqbal, J., Weisenburger, D. D., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905680 · Cited by 1,262
Imai, K., Matsuyama, S., Miyake, S., Suga, K., & Nakachi, K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03231-1 · Cited by 1,190
T-cell exhaustion in the tumor microenvironment
Jiang, Y., Li, Y., & Zhu, B. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.162 · Cited by 1,157
Lesokhin, A. M., Ansell, S. M., Armand, P., Scott, E. C., Halwani, A., Gutierrez, M., Millenson, M. M., Cohen, A. D., Schuster, S. J., Lebovic, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.9789 · Cited by 1,001
Chen, R., Zinzani, P. L., Fanale, M. A., Armand, P., Johnson, N. A., Brice, P., Radford, J., Ribrag, V., Molin, D., Vassilakopoulos, T. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1316 · Cited by 989
Younes, A., Santoro, A., Shipp, M., Zinzani, P. L., Timmerman, J. M., Ansell, S., Armand, P., Fanale, M., Ratanatharathorn, V., Kuruvilla, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30167-x · Cited by 927
Fehniger, T. A., Cooper, M. A., Nuovo, G. J., Cella, M., Facchetti, F., Colonna, M., & Caligiuri, M. A. (2003) · Blood · doi:10.1182/blood-2002-09-2876 · Cited by 857
Chen, B. J., Chapuy, B., Ouyang, J., Sun, H. H., Roemer, M. G. M., Xu, M. L., Yu, H., Fletcher, C. D. M., Freeman, G. J., Shipp, M. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0855 · Cited by 843
Benson, D. M., Bakan, C. E., Mishra, A., Hofmeister, C. C., Efebera, Y., Becknell, B., Baiocchi, R. A., Zhang, J., Yu, J., Smith, M. K., et al. (2010) · Blood · doi:10.1182/blood-2010-02-271874 · Cited by 807
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Roemer, M. G. M., Advani, R. H., Ligon, A. H., Natkunam, Y., Redd, R. A., Homer, H., Connelly, C. F., Sun, H. H., Daadi, S. E., Freeman, G. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.4482 · Cited by 791
Armand, P., Shipp, M. A., Ribrag, V., Michot, J.-M., Zinzani, P. L., Kuruvilla, J., Snyder, E. S., Ricart, A. D., Balakumaran, A., Rose, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3467 · Cited by 670
A comprehensive transcriptional portrait of human cancer cell lines
Klijn, C., Durinck, S., Stawiski, E. W., Haverty, P. M., Jiang, Z., Liu, H., Degenhardt, J., Mayba, O., Gnad, F., Liu, J., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3080 · Cited by 660
The tumour microenvironment in B cell lymphomas
Scott, D. W., & Gascoyne, R. D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3774 · Cited by 552
Campbell, J. J., Qin, S., Unutmaz, D., Soler, D., Murphy, K. E., Hodge, M. R., Wu, L., & Butcher, E. C. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6477 · Cited by 517
Obermajer, N., Muthuswamy, R., Lesnock, J., Edwards, R. P., & Kalinski, P. (2011) · Blood · doi:10.1182/blood-2011-07-365825 · Cited by 497
Kiyasu, J., Miyoshi, H., Hirata, A., Arakawa, F., Ichikawa, A., Niino, D., Sugita, Y., Yufu, Y., Choi, I., Abe, Y., et al. (2015) · Blood · doi:10.1182/blood-2015-02-629600 · Cited by 464
PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
Goodman, A., Patel, S. P., & Kurzrock, R. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.168 · Cited by 461
Challa-Malladi, M., Lieu, Y. K., Califano, O., Holmes, A. B., Bhagat, G., Murty, V. V., Dominguez-Sola, D., Pasqualucci, L., & Dalla-Favera, R. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.006 · Cited by 439
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
Xu-Monette, Z. Y., Zhou, J., & Young, K. H. (2018) · Blood · doi:10.1182/blood-2017-07-740993 · Cited by 433
Chiesa, M. D., Carlomagno, S., Frumento, G., Balsamo, M., Cantoni, C., Conte, R., Moretta, L., Moretta, A., & Vitale, M. (2006) · Blood · doi:10.1182/blood-2006-03-006700 · Cited by 399
Human CD56bright NK Cells: An Update
Michel, T., Poli, A., Cuapio, A., Briquemont, B., Iserentant, G., Ollert, M., & Zimmer, J. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502570 · Cited by 395
Novel immunotherapies in lymphoid malignancies
Batlevi, C. L., Matsuki, E., Brentjens, R. J., & Younes, A. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.187 · Cited by 260
Gandhi, M. K., Lambley, E., Duraiswamy, J., Dua, U., Smith, C., Elliott, S., Gill, D., Marlton, P., Seymour, J., & Khanna, R. (2006) · Blood · doi:10.1182/blood-2006-04-015164 · Cited by 255
Self-citationMia, S., Warnecke, A., Zhang, X. ‐., Malmström, V., & Harris, R. A. (2014) · Scandinavian Journal of Immunology · doi:10.1111/sji.12162 · Cited by 251
Immunosuppressive CD14+HLA-DRlow/− monocytes in B-cell non-Hodgkin lymphoma
Lin, Y., Gustafson, M. P., Bulur, P. A., Gastineau, D. A., Witzig, T. E., & Dietz, A. B. (2011) · Blood · doi:10.1182/blood-2010-05-283820 · Cited by 244
Human NK cell receptors/markers: A tool to analyze NK cell development, subsets and function
Montaldo, E., Zotto, G. D., Chiesa, M. D., Mingari, M. C., Moretta, A., Maria, A. D., & Moretta, L. (2013) · Cytometry Part A · doi:10.1002/cyto.a.22302 · Cited by 218
Roemer, M. G. M., Advani, R. H., Redd, R. A., Pinkus, G. S., Natkunam, Y., Ligon, A. H., Connelly, C. F., Pak, C. J., Carey, C. D., Daadi, S. E., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0201 · Cited by 189
McClanahan, F., Hanna, B., Miller, S., Clear, A. J., Lichter, P., Gribben, J. G., & Seiffert, M. (2015) · Blood · doi:10.1182/blood-2015-01-622936 · Cited by 188
Kim, G. G., Donnenberg, V. S., Donnenberg, A. D., Gooding, W. E., & Whiteside, T. L. (2007) · Journal of Immunological Methods · doi:10.1016/j.jim.2007.05.013 · Cited by 152
Greaves, P., Clear, A. J., Coutinho, R., Wilson, A., Matthews, J., Owen, A., Shanyinde, M., Lister, T. A., Calaminici, M., & Gribben, J. G. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.9881 · Cited by 150
Feng, Z., Puri, S., Moudgil, T. L., Wood, W. J., Hoyt, C. C., Wang, C., Urba, W. J., Curti, B. D., Bifulco, C. B., & Fox, B. A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0091-z · Cited by 138
Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma
Jones, K., Nourse, J. P., Keane, C., Bhatnagar, A., & Gandhi, M. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1024 · Cited by 132
Self-citationBaessler, T., Charton, J. E., Schmiedel, B. J., Grünebach, F., Krusch, M., Wacker, A., Rammensee, H., & Salih, H. R. (2009) · Blood · doi:10.1182/blood-2009-06-227934 · Cited by 130
Role of the tumor microenvironment in mature B-cell lymphoid malignancies
Fowler, N. H., Cheah, C. Y., Gascoyne, R. D., Gribben, J. G., Neelapu, S. S., Ghia, P., Bollard, C. M., Ansell, S., Curran, M. A., Wilson, W. H., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.139493 · Cited by 121
Kiaii, S., Clear, A. J., Ramsay, A. G., Davies, D. C., Sangaralingam, A., Lee, A. R. I., Calaminici, M., Neuberg, D. S., & Gribben, J. G. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2137 · Cited by 120
The IL-12 Signature: NK Cell Terminal CD56+high Stage and Effector Functions
Loza, M. J., & PERUSSIA, B. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.88 · Cited by 114
Granzin, M., Soltenborn, S., Müller, S., Kollet, J., Berg, M., Cerwenka, A., Childs, R. W., & Huppert, V. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2015.03.611 · Cited by 108
Keane, C., Gill, D. S., Vari, F., Cross, D., Griffiths, L. R., & Gandhi, M. K. (2013) · American Journal of Hematology · doi:10.1002/ajh.23398 · Cited by 104
Self-citationKeane, C., Vari, F., Hertzberg, M., Cao, K. L., Green, M. R., Han, E., Seymour, J. F., Hicks, R. J., Gill, D. S., Crooks, P., et al. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00150-7 · Cited by 99
Self-citationKeane, C., Gould, C., Jones, K., Hamm, D. E., Talaulikar, D., Ellis, J. J., Vari, F., Birch, S. E., Han, E., Wood, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1576 · Cited by 88
Self-citationVisualization of Microscopy‐Based Spectral Imaging Data from Multi‐Label Tissue Sections
Mansfield, J. R., Hoyt, C. C., & Levenson, R. M. (2008) · Current Protocols in Molecular Biology · doi:10.1002/0471142727.mb1419s84 · Cited by 86
Tadmor, T., Fell, R., Polliack, A., & Attias, D. (2012) · Hematological Oncology · doi:10.1002/hon.2019 · Cited by 83
Swift, B. E., Williams, B. A., Kosaka, Y., Wang, X.-H., Medin, J. A., Viswanathan, S., Martínez‐López, J., & Keating, A. (2012) · Haematologica · doi:10.3324/haematol.2011.054254 · Cited by 74
Hertzberg, M., Gandhi, M. K., Trotman, J., Butcher, B., Taper, J., Johnston, A., Gill, D. S., Ho, S., Cull, G., Fay, K. C., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.154039 · Cited by 57
Self-citationExpansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders.
Jones, K., Nourse, J., Morrison, L. E., Nguyen-Van, D., Moss, D., Burrows, S., & Gandhi, M. (2010) · Blood · doi:10.1182/blood-2010-03-274076 · Cited by 56
Self-citationJones, K., Wockner, L. F., Brennan, R. M., Keane, C., Chattopadhyay, P. K., Roederer, M., Price, D. A., Cole, D. K., Hassan, B., Beck, K., et al. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12716 · Cited by 46
Self-citationA distinct distribution of natural killer cell subgroups in human tissues and blood
Möller, M. J., Kammerer, R., & von Kleist, S. (1998) · International Journal of Cancer · Cited by 33
McKee, S. J., Tuong, Z. K., Kobayashi, T., Doff, B. L., Soon, M. S. F., Nissen, M. D., Lam, P. Y., Keane, C., Vari, F., Moi, D., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1393599 · Cited by 22
Self-citationArpon, D. R., Gandhi, M. K., & Martin, J. H. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12318 · Cited by 8
Self-citation
Cited by
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,392
Exploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,276
Natural killer cells and other innate lymphoid cells in cancer
Chiossone, L., Dumas, P.-Y., Vienne, M., & Vivier, E. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0061-z · Cited by 1,007
Natural killer cells in cancer biology and therapy
Wu, S.-Y., Fu, T., Jiang, Y.-Z., & Shao, Z.-M. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01238-x · Cited by 863
“Meanwhile, the interaction of PD-1 NK cells and PD-L1 monoctyes/macrophages in Hodgkin lymphoma results in immune evasion, which can be reversed by PD-1 blockade [149].”
BackgroundContribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99317 · Cited by 817
Metadata
- Authors
- Vari, F., Arpon, D., Keane, C., Hertzberg, M. S., Talaulikar, D., Jain, S., Cui, Q., Han, E., Tobin, J., Bird, R., Cross, D., Hernandez, A., Gould, C., Birch, S., & Gandhi, M. K.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2018-04-19
- Volume
- 131
- Issue
- 16
- Pages
- 1809-1819
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2785652708
- Cited by
- 313
- References
- 62
- FWCI
- 24.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.